Augmented Inhibition of CYP3A4 in Human Primary Hepatocytes by Ritonavir Solid Drug Nanoparticles

Molecular Pharmaceutics
Philip MartinAndrew Owen

Abstract

Ritonavir is a protease inhibitor utilized primarily as a pharmaco-enhancer with concomitantly administered antiviral drugs including other protease inhibitors. However, poor tolerance, serious side effects, and toxicities associated with drug-drug interactions are common during exposure to ritonavir. The aim of this work was to investigate the impact of nanoformulation on ritonavir pharmacological properties. Emulsion-templated freeze-drying techniques were used to generate ritonavir (10 wt %) solid drug nanoparticle formulations. A total of 68 ritonavir formulations containing various mixtures of excipients were assessed for inhibition of CYP3A4 in baculosomes and primary human hepatocytes. Accumulation and cytotoxicity were assessed in HepG2 (hepatocytes), Caco-2 (intestinal), THP-1 (monocytes), A-THP-1 (macrophage), and CEM (lymphocytes). Transcellular permeation across Caco-2 cells was also assessed. From 68 solid drug nanoparticle formulations tested, 50 (73.5%) for baculosome and 44 (64.7%) for human primary hepatocytes exhibited enhanced CYP3A4 inhibition relative to an aqueous ritonavir solution. Sixty-one (89.7%) and 49 (72%) solid drug nanoformulations had higher apical to basal permeation across Caco-2 cells than aq...Continue Reading

References

Jul 10, 1996·JAMA : the Journal of the American Medical Association·C C CarpenterP A Volberding
May 1, 1997·Antimicrobial Agents and Chemotherapy·A HsuJ M Leonard
Nov 13, 1998·Clinical Pharmacokinetics·A HsuR J Bertz
Sep 2, 1999·Journal of Controlled Release : Official Journal of the Controlled Release Society·T NakanishiT Mayumi
Apr 25, 2000·Drugs·A Bardsley-Elliot, G L Plosker
Aug 21, 2001·Biological & Pharmaceutical Bulletin·T SakaedaM Hashida
Jan 28, 2003·Progress in Lipid Research·David Y Hui
Feb 21, 2003·European Journal of Pharmaceutical Sciences : Official Journal of the European Federation for Pharmaceutical Sciences·Elaine Merisko-LiversidgeEugene R Cooper
Aug 22, 2003·Organic & Biomolecular Chemistry·Ashraf Brik, Chi-Huey Wong
Dec 6, 2003·The Journal of Antimicrobial Chemotherapy·Robert K Zeldin, Richard A Petruschke
Dec 30, 2003·Journal of Medicinal Chemistry·Michal ViethPhilip A Hipskind
May 26, 2004·International Journal of Pharmaceutics·Gilles CornaireGeorges Houin
Nov 4, 2004·The Journal of Pharmacology and Experimental Therapeutics·C Steven ErnestDavid R Jones
Jan 8, 2005·Clinical Pharmacology and Therapeutics·Barbara J RingDiane L Phillips
Mar 4, 2005·Drug Metabolism and Disposition : the Biological Fate of Chemicals·Ping ZhaoCaroline A Lee
Feb 10, 2006·Drug Metabolism and Disposition : the Biological Fate of Chemicals·Mary F PaineDarryl C Zeldin
Mar 7, 2006·Nature Reviews. Drug Discovery·Gergely SzakácsMichael M Gottesman
Apr 13, 2006·Nano Letters·B Devika ChithraniWarren C W Chan
May 9, 2006·Drug Metabolism and Disposition : the Biological Fate of Chemicals·Dermot F McGinnityRobert J Riley
Aug 15, 2006·JAMA : the Journal of the American Medical Association·Scott M HammerUNKNOWN International AIDS Society-USA panel
Apr 25, 2007·Cancer Treatment Reviews·S HarmsenJ H M Schellens
Jul 16, 2008·Analytical and Bioanalytical Chemistry·Emre M Isin, F Peter Guengerich
Aug 8, 2008·Nature Nanotechnology·Haifei ZhangSteven P Rannard
Nov 26, 2008·Small·Manuela Semmler-BehnkeWolfgang Brandau
Apr 18, 2009·Biomaterials·Stefaan J H SoenenMarcel De Cuyper
May 19, 2009·Journal of Controlled Release : Official Journal of the Controlled Release Society·Alejandro SosnikAngel M Carcaboso
Jul 4, 2009·Nanomedicine·Ari Nowacek, Howard E Gendelman
Nov 17, 2009·Advanced Drug Delivery Reviews·José das NevesBruno Sarmento
Jan 1, 2010·Clinical Pharmacology and Therapeutics·A A MathiasB P Kearney
Jan 28, 2010·Drug Metabolism and Disposition : the Biological Fate of Chemicals·Feng LiXiaochao Ma
Feb 18, 2010·Antimicrobial Agents and Chemotherapy·Gerben van 't KloosterLieven Baert

❮ Previous
Next ❯

Citations

Jan 24, 2018·Nature Communications·Rahul P BakshiTheresa A Shapiro
Nov 2, 2019·Expert Opinion on Drug Metabolism & Toxicology·Dario CattaneoGiuliano Rizzardini
Jun 2, 2016·Polymers·Yolanda Alvarado PérezFrancisco A Riera Rodríguez
Jan 6, 2021·Canadian Journal of Physiology and Pharmacology·Peng WangJia-le Chen

❮ Previous
Next ❯

Related Concepts

Related Feeds

CREs: Gene & Cell Therapy

Gene and cell therapy advances have shown promising outcomes for several diseases. The role of cis-regulatory elements (CREs) is crucial in the design of gene therapy vectors. Here is the latest research on CREs in gene and cell therapy.

Antivirals (ASM)

Antivirals are medications that are used specifically for treating viral infections. Discover the latest research on antivirals here.

Antivirals

Antivirals are medications that are used specifically for treating viral infections. Discover the latest research on antivirals here.